DRUG · Nasdaq · CIK 0001827401

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES INC.’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 2, 2026. Its EDGAR record lists 1 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2024
—
Net income, FY2024
-CAD 2.8M
Form 4 filings on record, past 12 months
1

Company overview

Legal name (as filed)
BRIGHT MINDS BIOSCIENCES INC.
Ticker
DRUG
SEC Central Index Key (CIK)
0001827401
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
CHICAGO, IL
State or country of incorporation
British Columbia, Canada
Fiscal year ends
September 30
SEC filer category
<br>Emerging growth company
Position in SEC ticker list
#2885 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from BRIGHT MINDS BIOSCIENCES INC.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in CAD; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2020n/aFY2021n/aFY2022n/aFY2023n/aFY2024
Net income
-CAD 480.4KFY2020-CAD 8.7MFY2021-CAD 15.0MFY2022-CAD 7.4MFY2023-CAD 2.8MFY2024
DRUG annual results
ItemFY2020
ended Sep 30, 2020		FY2021
ended Sep 30, 2021		FY2022
ended Sep 30, 2022		FY2023
ended Sep 30, 2023		FY2024
ended Sep 30, 2024
Revenue—————
Net income-CAD 480.4K-CAD 8.7M-CAD 15.0M-CAD 7.4M-CAD 2.8M
Diluted EPS-CAD 0.13-CAD 4.82-CAD 6.06-CAD 1.98-CAD 0.65
Total assetsCAD 880.2KCAD 20.0MCAD 12.1MCAD 6.9MCAD 6.1M
Cash and equivalentsCAD 799.9KCAD 19.8MCAD 11.6MCAD 6.7MCAD 5.7M

XBRL tags used: netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

DRUG latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Dec 31, 202420-FAnnual report of a foreign private issuer· period Sep 30, 2024Document · Index
Oct 2, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
Dec 23, 202540-FAnnual report of certain Canadian issuers· period Sep 30, 2025Document · Index

Recent SEC filings

The 40 newest documents filed by or about BRIGHT MINDS BIOSCIENCES INC., by form type:

6-K ×16SCHEDULE 13G/A ×11SCHEDULE 13G ×3424B5 ×2FWP ×24 ×1S-8 ×1SCHEDULE 13D/A ×1F-X ×140-F ×16-K/A ×1
DRUG recent filings
FiledFormWhat it isOriginal
Oct 2, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
Oct 1, 20266-KReport of a foreign private issuer· period Sep 30, 2026Document · Index
Aug 17, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 13, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Aug 12, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 2, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jun 3, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
Jun 2, 20266-KReport of a foreign private issuer· period Jan 20, 2026Document · Index
May 28, 20266-KReport of a foreign private issuer· period May 26, 2026Document · Index
May 20, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 15, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
May 12, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 30, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 30, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 28, 2026Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 13, 20266-KReport of a foreign private issuer· period Dec 31, 2025Document · Index
Feb 6, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 9, 20266-KReport of a foreign private issuer· period Jan 9, 2026Document · Index
Jan 9, 20266-KReport of a foreign private issuer· period Jan 7, 2026Document · Index
Jan 9, 2026424B5424B5Document · Index
Jan 8, 20266-KReport of a foreign private issuer· period Jan 7, 2026Document · Index
Jan 7, 20266-KReport of a foreign private issuer· period Jan 6, 2026Document · Index
Jan 7, 20266-KReport of a foreign private issuer· period Jan 7, 2026Document · Index
Jan 7, 2026FWPFWPDocument · Index
Jan 7, 2026FWPFWPDocument · Index
Jan 7, 2026424B5424B5Document · Index
Jan 6, 20266-KReport of a foreign private issuer· period Jan 6, 2026Document · Index
Jan 5, 20266-KReport of a foreign private issuer· period Jan 5, 2026Document · Index
Dec 23, 2025F-XF-XDocument · Index
Dec 23, 202540-FAnnual report of certain Canadian issuers· period Sep 30, 2025Document · Index
Nov 17, 20256-KReport of a foreign private issuer· period Nov 17, 2025Document · Index
Nov 17, 20256-K/A6-K/A· period Nov 6, 2025Document · Index
Nov 14, 2025SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Nov 13, 2025SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Nov 12, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index

Insider filing activity

1 Form 4 filings appear in BRIGHT MINDS BIOSCIENCES INC.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Illinois

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001827401 and XBRL company facts. BRIGHT MINDS BIOSCIENCES INC. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.